Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested.
HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.
HQ Team August 4, 2024: The WHO has warned about the rising global incidence of hypervirulent and multi-resistant Klebsiella Pneumoniae (hvKp) infections. The.
The SARS-CoV-2 virus was detected in six backyard species in the southeastern US state of Virginia with unique viral mutations with lineages closely.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.
HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.